UBS upgraded West Pharmaceutical (WST) to Buy from Neutral with a price target of $390, up from $350. The firm has incremental confidence in a positive mix shift driven by Annex 1 regulations, wearable injectors, and GLP-1 tailwinds, and tells investors in a research that coupled with a view that destocking headwinds should dissipate soon, the combination drives confidence West can return to long- range plan growth earlier than expected, driving stock performance.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST: